NASDAQ:ORMP Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free ORMP Stock Alerts $2.20 -0.14 (-5.98%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$2.20▼$2.3350-Day Range$2.20▼$2.9652-Week Range$1.67▼$4.36Volume204,073 shsAverage Volume148,772 shsMarket Capitalization$89.39 millionP/E Ratio8.46Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Oramed Pharmaceuticals alerts: Email Address Oramed Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.75% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.25) to ($0.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.69 out of 5 starsMedical Sector686th out of 931 stocksPharmaceutical Preparations Industry323rd out of 433 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Oramed Pharmaceuticals.Read more about Oramed Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.75% of the outstanding shares of Oramed Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverOramed Pharmaceuticals has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oramed Pharmaceuticals has recently decreased by 6.16%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOramed Pharmaceuticals does not currently pay a dividend.Dividend GrowthOramed Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ORMP. Previous Next 2.5 News and Social Media Coverage News SentimentOramed Pharmaceuticals has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Oramed Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest7 people have searched for ORMP on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.00% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.73% of the stock of Oramed Pharmaceuticals is held by institutions.Read more about Oramed Pharmaceuticals' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Oramed Pharmaceuticals are expected to decrease in the coming year, from ($0.25) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oramed Pharmaceuticals is 8.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Oramed Pharmaceuticals is 8.46, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 149.67.Price to Book Value per Share RatioOramed Pharmaceuticals has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Oramed Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin AnalyticsWall Street Legend Warns: "A Strange Day Is Coming to America"Get Your Cash Out of U.S. Banks Immediately Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making.Click here to learn more. About Oramed Pharmaceuticals Stock (NASDAQ:ORMP)Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.Read More ORMP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ORMP Stock News HeadlinesMay 23, 2024 | americanbankingnews.comQ3 2024 EPS Estimates for Oramed Pharmaceuticals Inc. Cut by Analyst (NASDAQ:ORMP)May 22, 2024 | americanbankingnews.comResearch Analysts Issue Forecasts for Oramed Pharmaceuticals Inc.'s Q1 2025 Earnings (NASDAQ:ORMP)May 21, 2024 | americanbankingnews.comOramed Pharmaceuticals (NASDAQ:ORMP) Receives "Neutral" Rating from HC WainwrightMay 18, 2024 | americanbankingnews.comOramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Crosses Below 200 Day Moving Average of $2.51May 12, 2024 | finance.yahoo.comOramed Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)May 10, 2024 | investorplace.comORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q1 2024March 16, 2024 | finance.yahoo.comORMP Apr 2024 2.500 putMarch 9, 2024 | finance.yahoo.comOramed Pharmaceuticals Full Year 2023 Earnings: Beats ExpectationsFebruary 21, 2024 | msn.comOramed to reinitiate pivotal type 2 diabetes trial after Phase III flopFebruary 20, 2024 | finanznachrichten.deOramed Pharmaceuticals Inc.: Oramed Letter to ShareholdersFebruary 20, 2024 | prnewswire.comOramed Letter to ShareholdersJanuary 24, 2024 | finance.yahoo.comORMP: Multiple Potential Applications for Proprietary Oral Protein Delivery PlatformNovember 28, 2023 | msn.comOramed Pharmaceuticals (ORMP) Price Target Increased by 36.51% to 4.39November 2, 2023 | msn.comOramed Pharmaceuticals (ORMP) Price Target Increased by 57.50% to 3.21October 6, 2023 | finance.yahoo.comOramed Pharmaceuticals (NASDAQ:ORMP) investors are sitting on a loss of 63% if they invested a year agoSeptember 21, 2023 | finance.yahoo.comOramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding CompanyAugust 2, 2023 | finance.yahoo.comOramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology GloballyJuly 25, 2023 | jp.reuters.comOramed Pharmaceuticals, Inc.June 20, 2023 | finance.yahoo.comOramed to Present at the 83rd American Diabetes Association ConferenceJune 17, 2023 | finance.yahoo.comOramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth PlansMay 30, 2023 | finance.yahoo.comORMP: Advancing Development Efforts in ChinaMay 24, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Hold Rating for Oramed Pharm (ORMP)May 18, 2023 | msn.comCanaccord Genuity Maintains Oramed Pharmaceuticals (ORMP) Hold RecommendationMay 18, 2023 | finance.yahoo.comOramed to Present at Novel Therapies for Type 2 Diabetes & Obesity SummitMay 16, 2023 | msn.comOramed Surges on New Diabetes TreatmentSee More Headlines Receive ORMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today5/28/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ORMP CUSIPN/A CIK1176309 Webwww.oramed.com Phone(844) 967-2633Fax972-2566-0004Employees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.26 Trailing P/E Ratio8.81 Forward P/E RatioN/A P/E GrowthN/ANet Income$5.53 million Net MarginsN/A Pretax Margin1,518.25% Return on Equity-3.83% Return on Assets-2.96% Debt Debt-to-Equity RatioN/A Current Ratio5.28 Quick Ratio5.28 Sales & Book Value Annual Sales$1.34 million Price / Sales69.43 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book0.57Miscellaneous Outstanding Shares40,630,000Free Float35,754,000Market Cap$93.04 million OptionableOptionable Beta1.87 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Nadav Kidron Esq. (Age 50)President, CEO & Executive Chairman Comp: $754.3kMr. David Silberman CPA (Age 40)CFO & Treasurer Comp: $259.53kDr. Miriam Kidron Ph.D. (Age 84)Chief Scientific Officer & Director Comp: $503.95kMr. Joshua Hexter (Age 54)Chief Operating & Business Officer Comp: $326.94kKey CompetitorsEntasis TherapeuticsNASDAQ:ETTXStealth BioTherapeuticsNASDAQ:MITOFibroBiologicsNASDAQ:FBLGVerrica PharmaceuticalsNASDAQ:VRCAShattuck LabsNASDAQ:STTKView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 23,165 shares on 5/20/2024Ownership: 0.057%Murchinson Ltd.Bought 329,495 shares on 5/16/2024Ownership: 3.395%Assenagon Asset Management S.A.Bought 18,659 shares on 4/24/2024Ownership: 0.046%BML Capital Management LLCSold 417,063 shares on 4/23/2024Ownership: 2.084%View All Institutional Transactions ORMP Stock Analysis - Frequently Asked Questions Should I buy or sell Oramed Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ORMP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORMP, but not buy additional shares or sell existing shares. View ORMP analyst ratings or view top-rated stocks. How have ORMP shares performed in 2024? Oramed Pharmaceuticals' stock was trading at $2.31 at the start of the year. Since then, ORMP stock has decreased by 4.8% and is now trading at $2.20. View the best growth stocks for 2024 here. When is Oramed Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ORMP earnings forecast. How were Oramed Pharmaceuticals' earnings last quarter? Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced its quarterly earnings data on Wednesday, March, 6th. The biotechnology company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.04. What other stocks do shareholders of Oramed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN). Who are Oramed Pharmaceuticals' major shareholders? Oramed Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Murchinson Ltd. (3.40%), BML Capital Management LLC (2.08%), Virtu Financial LLC (0.06%), Assenagon Asset Management S.A. (0.05%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Kevin Rakin, Michael Rabinowitz, Nadav Kidron and Yadin Rozov. View institutional ownership trends. How do I buy shares of Oramed Pharmaceuticals? Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ORMP) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersDigitizing the $11T commodities sector with one tiny stockResource Stock DigestBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsElon’s New Device is About to Shock the WorldInvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsBiden replacement revealed?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
